Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout
Cidara Therapeutics, Inc.'s CD388's strong phase 2b results significantly de-risk CDTX and highlight its potential as a superior flu prophylactic, especially for high-risk patients. Multiple short-term catalysts—including FDA meeting, BARDA funding, potential early start of phase 3 and breakthrough designation—could accelerate development and drive further upside. Cidara is well-funded through phase 3, with $516.9M in cash, and is an attractive acquisition candidate after its impressive trial results.
Cidara Therapeutics, Inc. (CDTX) Q2 2025 Earnings Call Transcript
Cidara Therapeutics, Inc. (NASDAQ:CDTX ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Frank L. Karbe - Chief Financial Officer Jeffrey L.
Cidara Therapeutics Advances CD388 To Phase 3, Reiterate Buy
Cidara Therapeutics' main value driver, CD388, recently achieved an impressive 76% protection in its Phase 2b trials. It also showed a compelling safety profile. In my view, CD388 now has a clear pathway to start its pivotal Phase 3 initiation relatively soon. CDTX raised roughly $250 million through stock. While this is relatively dilutive, the resulting valuation multiples still seem reasonable for new investors.
Cidara Therapeutics: All Stars Aligning In Favor Of CD388
Cidara Therapeutics' CD388 is a long-acting influenza antiviral aimed at providing universal protection with a single yearly dose for each flu season. In contrast to vaccines, CD388's efficacy is not dependent on circulating strains or on an intact patient immune system. CD388 is ideal for pandemic preparedness and for high-risk patients. Readout of a randomized ph2b trial of CD388 is expected by the end of June, with the potential to serve as one of the two needed trials for approval.
Cidara Therapeutics, Inc. (CDTX) Q1 2025 Earnings Call Transcript
Cidara Therapeutics, Inc. (NASDAQ:CDTX ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Brian Ritchie - LifeSci Advisors Jeffrey Stein - President and Chief Executive Officer Frank Karbe - Chief Financial Officer Nicole Davarpanah - Chief Medical Officer Les Tari - Chief Scientific Officer Jim Beitel - Chief Business Officer Conference Call Participants Eric Schmidt - Cantor Fitzgerald Seamus Fernandez - Guggenheim Gregory Renza - RBC Capital Markets Joseph Stringer - Needham & Company Roy Buchanan - Citizens Bank Operator Greetings. Welcome to Cidara's Q1 2025 Earnings Call.
Cidara Therapeutics: Strong Buy On Imminent Data Readout For Lead Flu Candidate
We initiate coverage on Cidara Therapeutics with a Strong Buy rating due to its strategic pivot to antiviral CD388 and promising Phase 2b trial data. Rezafungin's successful approval and divestiture to Mundipharma validate Cidara's development capabilities and free resources for advancing CD388. CD388 shows potential for season-long influenza protection, with promising Phase 2a data and a well-funded Phase 2b trial targeting high-risk patients.
Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics (CDTX) is a Great Choice
Does Cidara Therapeutics (CDTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know
The consensus price target hints at a 64.5% upside potential for Cidara Therapeutics (CDTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy?
Cidara Therapeutics, Inc. (CDTX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CDTX's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Cidara: Potential To Change Flu Prophylaxis Landscape With CD388
Results from phase 2b NAVIGATE study, using CD388 as a prophylaxis for Flu, expected to be released Q3 of 2025. CD388 offers broad influenza A and B coverage regardless of strain type and even effective in immunocompromised patients, and could revolutionize flu treatment. The global influenza vaccine market is projected to grow to $17.77 billion by 2032.
